Latest News

Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug

March 22, 2012. CAMBRIDGE, UK – XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.  The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and demonstrated good...




Seroba Co-leads a €1.2 million New Investment in Biosensia.

Dublin, Ireland, 9 November 2011.  Biosensia, a point of care diagnostics company, has secured €1.2 million in new funding as part of the company’s plans to advance its regulatory and commercial strategy for its platform in Europe and the US. The funding round was co-led by Seroba Bioventures and ACT Venture Capital and also included existing investors, Atlantic Bridge. ...


< back to home page